Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 995 of 6351
-
Blood test may spot hidden cancer cells after surgery
Knowledge-focused OngoingIn clinical practice, there are currently no biomarkers that can guide colorectal cancer treatment in the primary and curative setting. Improved biomarker-based adjuvant treatments would be of greatest value in order to reduce the risk of relapse. There are reasons to believe tha…
Sponsor: Anna Martling • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
Can a robot help stroke survivors with HIV walk again?
Symptom relief OngoingToday, nearly 37 million people are living with HIV (PLHIV) worldwide and 30 to 40% of them will have neurologic complications leading to disability. Our long-term working hypothesis is that an effective solution for increasing rehabilitation access in Botswana and improving func…
Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
New trial tests best timing for rectal cancer chemo
Disease control Recruiting nowThis is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure
Phase 3 • Sponsor: Ralf Hofheinz • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New PNH drug crovalimab faces off against eculizumab in phase 3 trial
Disease control OngoingA study designed to evaluate the safety of crovalimab with eculizumab in participants with PNH currently treated with complement inhibitors. This study will enroll approximately 190 participants.
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Liver transplants offer new hope for colorectal cancer patients
Disease control Recruiting nowThis is a single-arm, single institution pilot registry of liver transplantation in patients with unresectable colorectal liver-only metastases at Weill Cornell Medical College. Patients with liver predominant colorectal liver metastases will be screened based on eligibility crit…
Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug risankizumab takes on standard therapy in Crohn's battle
Disease control OngoingCrohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankizumab works compared to ustekinumab. This study will assess change in Crohn's Disease Activity Index (CDAI). Risankizumab is an inv…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New Scan-Guided therapy could delay hormone therapy for prostate cancer patients
Disease control Recruiting nowThis phase II trial studies how well prostate specific membrane antigen (PSMA) or fluciclovine positron emission tomography (PET)/computed tomography (CT) site-directed therapy works for treating patients with prostate cancer. PSMA or fluciclovine PET/CT may detect prostate cance…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Can surveillance catch birth defects early in HIV-Affected pregnancies?
Knowledge-focused Recruiting nowThe purpose of this study is to develop a pharmacovigilance (PV) surveillance program to monitor adverse pregnancy and infant outcomes, including the presence of congenital abnormalities, among HIV-positive and HIV-negative women and their infants at clinical sites affiliated wit…
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
New combo therapy aims to shrink spleens in bone marrow cancer patients
Disease control CompletedMyelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue. It can also cause a low number of blood-clotting cells ca…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New combo therapy shows promise for hard-to-treat lung cancer
Disease control CompletedETOP 15-19 ABC-lung is an international, multi-centre open-label, randomized phase II trial with two non-comparative parallel arms of atezolizumab plus bevacizumab with carboplatin-paclitaxel (Arm A) or atezolizumab, bevacizumab and pemetrexed (Arm B) in patients with stage IIIB-…
Phase 2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Gene therapy for sanfilippo a: does it last?
Disease control By invitation onlyThe main objective of this study is to evaluate the safety/tolerability and efficacy of UX111 (previously known as ABO-102) in participants with Mucopolysaccharidosis IIIA (MPS IIIA).
Phase 3 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New combo therapy shows promise for Drug-Resistant lung cancer
Disease control OngoingThis study will compare the activity of the combination of savolitinib and osimertinib against the combination of savolitinib with placebo to osimertinib in patients with Epidermal Growth Factor Receptor Mutation Positive and MET amplified, locally advanced or metastatic non-smal…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Can an immune booster shrink Hard-to-Treat stomach tumors?
Disease control Stopped earlyThis is a single-arm, multicenter, phase 2 study to assess the efficacy and safety of Toripalimab Injection (JS001) in patients with advanced recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma who have failed at least 2 prior lines of therapy and are posi…
Phase 2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New combo aims to wipe out hidden breast cancer cells after standard treatment
Disease control Recruiting nowThis study looks to advance a novel and potent strategy to eliminate minimal residual disease (MRD) in triple negative breast cancer (TNBC) present even after multimodal treatment, thereby improving survival and increasing cure rate in this aggressive cancer. Patients with locall…
Phase 1/2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Promising combo targets hard-to-treat childhood cancer
Disease control OngoingDifluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
Phase 2 • Sponsor: Giselle Sholler • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug shows promise for rare joint tumor
Disease control OngoingThis study will assess pexidartinib in adult participants with symptomatic TGCT that is associated with severe morbidity or functional limitations and not amendable to improvement with surgery.
Phase 3 • Sponsor: Daiichi Sankyo Co., Ltd. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Glowing tumor surgery: new hope for kids with brain cancer?
Disease control CompletedIn this prospective, open, single-armed, multicenter, phase II study for application of 5-ALA in children and adolescents with brain tumors 80 patients will be investigated. Primary objective of the study is to determine the safety of 5-ALA for fluorescence-guided resections in …
Phase 2 • Sponsor: Universität Münster • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Hospital heart pill may prevent repeat crises
Disease control CompletedThis is an international, multicenter, parallel-group, randomized, double-blind, placebo-controlled trial in patients who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin versus placebo on the cl…
Phase 4 • Sponsor: The TIMI Study Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New triple-drug attack aims to revive immune response in hard-to-treat melanoma
Disease control OngoingThe purpose of this study is to find out if the administration of Interleukin-2 concurrently with ipilimumab followed by Nivolumab will result in improved anti-cancer activity and if it is effective for advanced melanoma.
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for rare liver disease: drug shows promise in reducing damage and symptoms
Disease control OngoingThe participants of this study will have confirmed Primary Biliary Cholangitis (PBC) with inadequate response or intolerance to ursodeoxycholic acid (which is a medication used in the management and treatment of cholestatic liver disease). PBC is a slowly progressive disease cha…
Phase 3 • Sponsor: Ipsen • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC